Introduction
Mark H. Einstein, MD, MS, Chair
Director, Clinical Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology and Women's Health
Montefiore Medical Center
Bronx, N.Y. Dr Einstein has received clinical grants from GlaxoSmithKline, Merck & Co., Inc., and Tigris Pharmaceuticals, Inc.
Milestones in Cervical Cancer Detection and Prevention: Significance in Clinical Practice
Mark H. Einstein, MD, MS, Chair
Improving HSIL and Glandular Disease Detection: What the Recent Data Show
Richard Lozano, MD
Director of Cytology
Pathology and Cytology Laboratories, Inc.
Lexington, Ky. Dr Lozano has nothing to disclose.
and
Harold J. Sauer, MD, FACOG
Associate Professor and Acting Chair
Department of Obstetrics and Gynecology and Reproductive Biology
Michigan State University
Lansing Dr Sauer has nothing to disclose.
Weighing the Costs and Benefits: Technologic Advances in Cervical Cancer Screening
Warner K. Huh, MD, FACOG, FACS
Assistant Professor
Division of Gynecologic Oncology
University of Alabama at Birmingham Dr Huh has received clinical grants from 3M Pharmaceuticals, Cytyc Corporation, GlaxoSmithKline, MGI PHARMA, Merck, Roche Molecular Systems, and Tigris Pharmaceuticals. He is a consultant to GlaxoSmithKline, MGI PHARMA, Roche Molecular Systems, and mtm laboratories AG.
Efficacy of HPV Screening Versus Liquid-Based Cervical Cytology and Imaging: What the Data Really Show
Michael Karram, MD, FACOG
President and Medical Director
Seven Hills Women's Health Centers
Cincinnati, Ohio Dr Karram has nothing to disclose.
and
Michael L. Krychman, MD
Associate Clinical Attending
Sexual Medicine Program
Memorial Sloan-Kettering Cancer Center
New York, N.Y. Dr Krychman is a consultant to Cytyc.
